By Billy Candra 
A groundbreaking study, presented at the American College of Cardiology’s Annual Scientific Session (ACC.25), reveals that mammograms, when enhanced by sophisticated artificial intelligence (AI) models, possess the potential to detect far more than just breast cancer. The findings underscore a significant paradigm shift, demonstrating how these routine breast cancer screening tools can also be leveraged to quantitatively assess the accumulation of calcium within the arteries of breast tissue – a crucial, yet often overlooked, indicator of cardiovascular health and future cardiac events. This represents a powerful opportunity for "opportunistic screening," transforming a single diagnostic procedure into a dual-purpose health assessment, particularly vital for women, who often face unique challenges in cardiovascular disease diagnosis and awareness.
The U.S. Centers for Disease Control and Prevention (CDC) advocates for regular mammograms, typically every one to two years, for middle-aged and older women as a primary defense against breast cancer. With approximately 40 million mammograms conducted annually across the United States, this ubiquitous screening offers an unparalleled platform for broader health surveillance. While breast artery calcifications (BAC) are visually discernible on these X-ray images, standard radiological practice historically has not included their quantification or routine reporting to patients or their primary care physicians. The new research, spearheaded by a team from Emory University and Mayo Clinic, introduces an innovative AI image analysis technique – a departure from previous AI models – that meticulously analyzes BAC and translates these observations into a comprehensive cardiovascular risk score. This advancement promises to bridge a critical diagnostic gap, offering a proactive approach to heart health.
The Silent Threat: Cardiovascular Disease in Women
Heart disease remains the foremost cause of death globally and in the United States, claiming more lives than all cancers combined. Alarmingly, it is frequently underdiagnosed in women, a demographic that often presents with atypical symptoms, leading to delayed or missed diagnoses. Compounding this issue is a persistent lack of awareness among women regarding their personal risk for cardiovascular disease (CVD). This study’s implications are profound in this context, suggesting that AI-enabled mammogram screening tools could significantly enhance the identification of women exhibiting early markers of CVD, maximizing the utility of a screening test that a vast majority of eligible women already undergo regularly.
A buildup of calcium in the arterial walls, medically termed atherosclerosis, is a definitive sign of cardiovascular damage. It is intrinsically linked to the early stages of heart disease and is often exacerbated by the natural aging process. Prior epidemiological studies have firmly established a correlation between the presence of calcium deposits in the arteries and an elevated risk of adverse cardiovascular events. Specifically, women identified with breast artery calcification have been shown to face a staggering 51% higher risk of experiencing heart disease and stroke compared to their counterparts without such calcifications. This substantial increase in risk highlights the urgency of developing effective, accessible screening methods to identify these at-risk individuals early.
Pioneering AI for Dual-Purpose Screening
The development of this novel AI-powered screening tool involved training a deep-learning model to meticulously segment calcified vessels within mammogram images. These calcifications typically manifest as bright, distinct pixels on X-rays. Unlike previous AI iterations that might have broadly identified calcification, this model’s segmentation approach allows for precise measurement and quantification of the calcium burden. This granular data, when integrated with electronic health record (EHR) data, enables the calculation of an individual’s future risk of cardiovascular events. Dr. Theo Dapamede, MD, PhD, a postdoctoral fellow at Emory University in Atlanta and the study’s lead author, emphasized the distinct advantage of this segmentation technique, stating, "We see an opportunity for women to get screened for cancer and also additionally get a cardiovascular screen from their mammograms. Our study showed that breast arterial calcification is a good predictor for cardiovascular disease, especially in patients younger than age 60. If we are able to screen and identify these patients early, we can refer them to a cardiologist for further risk assessment."
The robustness of this AI model is further bolstered by the extensive dataset utilized for its training and validation. Researchers leveraged a massive repository of images and health records from over 56,000 patients who underwent mammography at Emory Healthcare between 2013 and 2020. Crucially, this dataset included a minimum of five years of follow-up electronic health records data for each patient, providing a rich historical context to correlate calcification levels with subsequent cardiovascular outcomes. This longitudinal data is instrumental in validating the predictive power of the AI model. "Advances in deep learning and AI have made it much more feasible to extract and use more information from images to inform opportunistic screening," Dr. Dapamede noted, underscoring the transformative potential of modern AI capabilities.
Unpacking the Study’s Key Findings
The comprehensive analysis demonstrated the new AI model’s impressive efficacy in characterizing patients’ cardiovascular risk, categorizing it as low, moderate, or severe based solely on mammogram images. The model was tasked with calculating the risk of mortality from any cause, as well as the risk of acute myocardial infarction (heart attack), stroke, or heart failure at two-year and five-year intervals. The results consistently indicated a direct correlation: the rate of these serious cardiovascular events escalated in tandem with increasing levels of breast arterial calcification. This trend was particularly pronounced and statistically significant in two key age demographics: women younger than 60 and those aged 60-80. Notably, this predictive power did not hold for women over 80, suggesting that for this older cohort, other cumulative risk factors might overshadow BAC as the primary determinant of cardiovascular events.
This age-specific predictive capability renders the tool especially valuable for providing an early warning of heart disease risk in younger women. Identifying these individuals early is paramount, as they stand to benefit most from timely interventions, lifestyle modifications, and targeted medical management, potentially altering the trajectory of their cardiovascular health. The study explicitly highlighted the disparities in event-free survival based on calcification levels. Women with the highest level of breast arterial calcification (exceeding 40 mm²) exhibited a significantly lower five-year rate of event-free survival compared to those with the lowest level (below 10 mm²). For instance, only 86.4% of individuals with severe BAC survived for five years without a major cardiovascular event, in stark contrast to 95.3% of those with minimal or no calcification. This translates to an approximate 2.8-fold increased risk of death within five years for patients presenting with severe breast arterial calcification when compared to those with little to no BAC.
Implications for Clinical Practice and Integrated Care
The findings of this study signal a potential paradigm shift in preventive cardiology and women’s health. The seamless integration of cardiovascular risk assessment into a routine breast cancer screening could dramatically increase the early detection rate of heart disease in women. This "opportunistic screening" approach leverages existing infrastructure and patient compliance, minimizing the need for additional appointments or specialized tests that might pose barriers to access or adherence.
For radiologists, this development could evolve their role beyond cancer detection to encompass a broader scope of health assessment. While currently, BAC is often noted incidentally, the AI tool provides a standardized, quantifiable metric, enabling radiologists to furnish clinicians with actionable data. This necessitates enhanced collaboration between radiology and cardiology departments, potentially leading to the establishment of new referral pathways and integrated care models. A woman identified with elevated BAC could be promptly referred to a cardiologist for a more comprehensive risk assessment, including traditional risk factor evaluation (e.g., blood pressure, cholesterol, diabetes), further imaging, and personalized intervention strategies.
The American Heart Association (AHA) and other cardiovascular health organizations have long championed increased awareness and early detection of heart disease in women. This AI-powered tool aligns perfectly with such advocacy efforts, providing a practical, scalable solution to address a critical unmet need. Public health bodies like the CDC would likely view this as a significant step forward in population health, offering a non-invasive, cost-effective method to identify at-risk individuals within a large, routinely screened population.
Timeline, Validation, and Future Horizons
The AI model, a collaborative effort between Emory Healthcare and Mayo Clinic, is currently in a research phase and not yet commercially available for clinical use. The path forward involves several crucial steps. First, the model must undergo rigorous external validation in diverse patient populations and healthcare settings to confirm its generalizability and accuracy. Following successful validation, it would require approval from the U.S. Food and Drug Administration (FDA) to ensure its safety and efficacy for widespread clinical application. Once these regulatory hurdles are cleared, researchers anticipate that the tool could be made commercially available, allowing other healthcare systems to integrate it seamlessly into their routine mammogram processing and follow-up care protocols.
Beyond breast arterial calcification, the researchers are actively exploring the potential to extend this AI methodology to assess other biomarkers for various conditions that might be discernible from mammogram images. This includes, but is not limited to, peripheral artery disease and kidney disease, both of which are closely linked to systemic vascular health. Such an expansion would further solidify the mammogram’s role as a multi-faceted diagnostic window into a woman’s overall health.
The ethical implications of AI in healthcare, particularly concerning data privacy, algorithmic bias, and informed consent, will also need careful consideration as such tools become more prevalent. Ensuring equitable access and avoiding exacerbation of existing health disparities will be paramount. However, the sheer potential for early, non-invasive detection of life-threatening conditions like heart disease, especially in an often-underserved demographic, presents a compelling case for continued research, development, and thoughtful implementation of this groundbreaking technology. This study represents a significant leap forward in leveraging existing medical imaging for comprehensive health insights, promising a future where a routine mammogram could literally be a lifesaver for both breast cancer and heart disease.